Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04817007 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

A Phase 1 study of Myelofibrosis, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 1
Development phase
216
Enrollment target
20
Study locations

NCT04817007 is a Phase 1 study of Myelofibrosis that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 216 participants, above the 192-participant average among 61 other Myelofibrosis trials with a reported enrollment target (13% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04817007, a Phase 1 study of Myelofibrosis, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
216 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib in participants with Dynamic International Prognostic Scoring System (DIPSS)-intermediate or high risk blood cancer. Part 1 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and Part 2 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and BMS-986158 alone.

Conditions Studied

Myelofibrosis

Interventions

  • DRUG Ruxolitinib
  • DRUG BMS-986158
  • DRUG Fedratinib

Study Locations (20)

Other

  • Local Institution - 0030 - Brest
  • Local Institution - 0008 - Marseille
  • Local Institution - 0027 - Nice
  • Local Institution - 0011 - Paris
  • Local Institution - 0010 - Villejuif

New South Wales

  • Local Institution - 0036 - Blacktown
  • Local Institution - 0032 - Wollongong

Victoria

  • Local Institution - 0007 - East Melbourne
  • Local Institution - 0006 - Heidelberg

Western Australia

  • Local Institution - 0041 - Nedlands
  • Local Institution - 0015 - West Perth

California

  • Local Institution - 0069 - Newport Beach

Florida

  • Local Institution - 0090 - Lake Mary

Louisiana

  • Local Institution - 0043 - New Orleans

Massachusetts

  • Local Institution - 0038 - Worcester

Trial Details

FieldValue
Enrollment Target 216 participants
Start Date 2021-03-22
Est. Completion 2026-05-31
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04817007

The ClinicalTrials.gov registry entry for NCT04817007 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 192-participant average among 61 other Myelofibrosis trials with a reported enrollment target (13% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 3 interventions - of which Ruxolitinib is the first listed.

NCT04817007 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, New South Wales, Victoria.

Frequently Asked Questions

What is clinical trial NCT04817007 about?

NCT04817007 is a clinical study titled "A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)". The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib in participants with Dynamic International Prognostic Scoring System (DIPSS)-intermediate or high risk blood cancer. Part 1 consists of BMS-98615...

What is the current status of trial NCT04817007?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 216 participants. The study started on 2021-03-22. Estimated completion is 2026-05-31.

What conditions does trial NCT04817007 study?

This clinical trial studies the following conditions: Myelofibrosis.

What interventions are being tested in trial NCT04817007?

The interventions under investigation include: Ruxolitinib (DRUG), BMS-986158 (DRUG), Fedratinib (DRUG).

Who is sponsoring clinical trial NCT04817007?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04817007 being conducted?

This trial has 20 study locations across California, Florida, Louisiana, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myelofibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myelofibrosis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.